GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (NAS:RVNC) » Definitions » Shiller PE Ratio

RVNC (Revance Therapeutics) Shiller PE Ratio : (As of Apr. 27, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Revance Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Revance Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Revance Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics Shiller PE Ratio Chart

Revance Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Revance Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Revance Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Revance Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revance Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Revance Therapeutics's Shiller PE Ratio falls into.


;
;

Revance Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Revance Therapeutics's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Revance Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.37/133.0289*133.0289
=-0.370

Current CPI (Sep. 2024) = 133.0289.

Revance Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -0.600 99.070 -0.806
201503 -0.650 99.621 -0.868
201506 -0.710 100.684 -0.938
201509 -0.810 100.392 -1.073
201512 -0.830 99.792 -1.106
201603 -0.710 100.470 -0.940
201606 -0.880 101.688 -1.151
201609 -0.640 101.861 -0.836
201612 -0.950 101.863 -1.241
201703 -0.940 102.862 -1.216
201706 -0.900 103.349 -1.158
201709 -1.010 104.136 -1.290
201712 -1.140 104.011 -1.458
201803 -0.970 105.290 -1.226
201806 -0.940 106.317 -1.176
201809 -0.910 106.507 -1.137
201812 -1.120 105.998 -1.406
201903 -0.850 107.251 -1.054
201906 -0.860 108.070 -1.059
201909 -0.960 108.329 -1.179
201912 -0.990 108.420 -1.215
202003 -1.150 108.902 -1.405
202006 -1.120 108.767 -1.370
202009 -1.340 109.815 -1.623
202012 -1.240 109.897 -1.501
202103 -1.080 111.754 -1.286
202106 -1.070 114.631 -1.242
202109 -1.100 115.734 -1.264
202112 -0.930 117.630 -1.052
202203 -0.940 121.301 -1.031
202206 -0.880 125.017 -0.936
202209 -1.170 125.227 -1.243
202212 -1.820 125.222 -1.933
202303 -0.740 127.348 -0.773
202306 -0.800 128.729 -0.827
202309 -1.630 129.860 -1.670
202312 -0.630 129.419 -0.648
202403 -0.580 131.776 -0.586
202406 -0.360 132.554 -0.361
202409 -0.370 133.029 -0.370

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Revance Therapeutics  (NAS:RVNC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Revance Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Revance Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Executives
Dwight Moxie officer: SVP, GC & Secretary 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Dustin S Sjuts officer: President 7555 GATEWAY BLVD, NEWARK CA 94560
Tobin Schilke officer: Chief Financial Officer 7000 SHORELINE COURT, #371, SOUTH SAN FRANCISCO CA 94080
Mark J Foley director ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Carey Oconnor Kolaja director C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, SUITE 1001, NASHVILLE TN 37203
Vlad Coric director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Aubrey Rankin director C/O REVANCE THERAPEUTICS, INC, 7555 GATEWAY BLVD, NEWARK CA 94560
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Olivia C Ware director 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Jill Beraud director C/O LEVI STRAUSS & CO., 1155 BATTERY STREET, SAN FRANCISCO CA 94111
L Daniel Browne director, officer: CEO and President 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Cyril Allouche officer: Principal Financial Officer 7555 GATEWAY BLVD., NEWARK CA 94560
Lauren P Silvernail officer: CFO, Seretary & EVP Corp Dev. 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Caryn Gordon Mcdowell officer: SVP, GC & Secretary 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080

Revance Therapeutics Headlines

From GuruFocus